These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34073490)

  • 21. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
    Falloon J; Ji F; Curtis C; Bart S; Sheldon E; Krieger D; Dubovsky F; Lambert S; Takas T; Villafana T; Esser MT
    Vaccine; 2016 May; 34(25):2847-54. PubMed ID: 27102821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults.
    Falsey AR; Walsh EE; Looney RJ; Kolassa JE; Formica MA; Criddle MC; Hall WJ
    J Med Virol; 1999 Oct; 59(2):221-6. PubMed ID: 10459160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.
    Piedra PA; Glezen WP; Kasel JA; Welliver RC; Jewel AM; Rayford Y; Hogerman DA; Hildreth SW; Paradiso PR
    Vaccine; 1995 Aug; 13(12):1095-101. PubMed ID: 7491817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein.
    Blunck BN; Aideyan L; Ye X; Avadhanula V; Ferlic-Stark L; Zechiedrich L; Gilbert BE; Piedra PA
    Vaccine; 2022 Jan; 40(3):536-543. PubMed ID: 34903371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus.
    Habibi MS; Jozwik A; Makris S; Dunning J; Paras A; DeVincenzo JP; de Haan CA; Wrammert J; Openshaw PJ; Chiu C;
    Am J Respir Crit Care Med; 2015 May; 191(9):1040-9. PubMed ID: 25730467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.
    Walsh EE; Wang L; Falsey AR; Qiu X; Corbett A; Holden-Wiltse J; Mariani TJ; Topham DJ; Caserta MT
    J Infect Dis; 2018 Jun; 218(2):208-217. PubMed ID: 29546402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus.
    Luchsinger V; Piedra PA; Ruiz M; Zunino E; Martínez MA; Machado C; Fasce R; Ulloa MT; Fink MC; Lara P; Avendaño LF
    Clin Infect Dis; 2012 Apr; 54(7):905-12. PubMed ID: 22238168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort.
    Sande CJ; Mutunga MN; Okiro EA; Medley GF; Cane PA; Nokes DJ
    J Med Virol; 2013 Nov; 85(11):2020-5. PubMed ID: 23983183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells.
    Cortjens B; Yasuda E; Yu X; Wagner K; Claassen YB; Bakker AQ; van Woensel JBM; Beaumont T
    J Virol; 2017 May; 91(10):. PubMed ID: 28275185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response.
    Borochova K; Niespodziana K; Focke-Tejkl M; Hofer G; Keller W; Valenta R
    Sci Rep; 2021 Feb; 11(1):3551. PubMed ID: 33574352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
    Shinoff JJ; O'Brien KL; Thumar B; Shaw JB; Reid R; Hua W; Santosham M; Karron RA
    J Infect Dis; 2008 Oct; 198(7):1007-15. PubMed ID: 18702606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody and Local Cytokine Response to Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults.
    Yu X; Lakerveld AJ; Imholz S; Hendriks M; Ten Brink SCA; Mulder HL; de Haan K; Schepp RM; Luytjes W; de Jong MD; van Beek J; van Kasteren PB
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32878928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells.
    Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zhang XJ; Zheng YB; Zheng YP; Hong T; He JS
    Int Immunopharmacol; 2017 May; 46():62-69. PubMed ID: 28259002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
    Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR
    J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness.
    Mazur NI; Horsley NM; Englund JA; Nederend M; Magaret A; Kumar A; Jacobino SR; de Haan CAM; Khatry SK; LeClerq SC; Steinhoff MC; Tielsch JM; Katz J; Graham BS; Bont LJ; Leusen JHW; Chu HY
    J Infect Dis; 2019 Jan; 219(1):59-67. PubMed ID: 30107412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.